12.06.18 -- Cell & Gene's Best Of November

Greetings Cell & Gene Readers,

Here are November’s most-read articles. From a background piece on Spark’s Katherine High to realistic commercialization strategies, these are original articles you’ll want to read — or read again. Enjoy.
 

Erin Harris, editor in chief
Follow me on Twitter

By Walter Colasante, Pascale Diesel, and Lev Gerlovin, CRA

While some new best practices to support gene and cell therapies are already in place or emerging, many companies working to develop these therapies will need to rethink the structure of their go-to-market models.

By Cathy Yarbrough, contributing editor

How Katherine High, M.D., cofounder, president, and head of R&D at Spark Therapeutics, helped reinvigorate the life sciences industry’s interest in gene therapy.

By Ed Miseta, chief editor, Clinical Leader

Jake LaPorte, head of digital development for Novartis, talks about how artificial intelligence (AI), the internet of things (IoT), and machine learning are all being leveraged for better clinical trials.

By GE Healthcare Life Sciences

Cell therapy manufacturing has been a complex, challenging, and costly process, but a new manufacturing solution seeks to change that.

By MilliporeSigma

Cell therapy, gene therapy, and RNA-based therapies are the classes of therapies we’re considering novel. How do you define a novel therapy versus a new drug? The answer is two-fold.

By Bio-Rad Laboratories, Inc.

Does the human body have the capability to heal itself? The idea of immunotherapy, harnessing the body’s own immune system to eradicate disease, has moved from the realm of possibility to something much more tangible.